'On standalone basis

Quarter ended December 2025 compared with Quarter ended December 2024.

Net sales (including other operating income) of Sanofi India has declined 18.47% to Rs 419.80 crore.  Operating profit margin has declined from 22.98% to 21.51%, leading to 23.67% decline in operating profit to Rs 90.30 crore.  Raw material cost as a % of total sales (net of stock adjustments) decreased from 16.94% to 14.13%.   Purchase of finished goods cost fell from 39.34% to 31.80%.   Employee cost increased from 8.87% to 11.42%.   Other expenses rose from 15.34% to 19.59%.   

Other income fell 52.54% to Rs 2.8 crore.  PBIDT fell 25.04% to Rs 93.1 crore.  Provision for interest up 50% to Rs 0.6 crore.  Loan funds declined from Rs 19.30 crore as of 31 December 2024 to Rs 17.80 crore as of 31 December 2025.  Inventories declined from Rs 499.80 crore as of 31 Dece...

• 

  (05-Feb-2025)

  Castrol India

  Expects EBITDA margin of 22%-25% for CY25
• 

  (10-Feb-2023)

  Deepak Nitrite

  Plans capex of about Rs 1500 crore for FY23 and FY24
• 

  (09-Feb-2023)

  Mayur Uniquoters

  Targets revenue of Rs 1000 crore in FY24
• 

  (31-Jan-2023)

  Tega industries

  Capex plan is US$ 30-32 million for next three years